SBI Life Q4FY26 APE up 6%; MOFSL trims target

What triggered attention on SBI Life

SBI Life Insurance (SBILIFE) reported a mixed set of new-business metrics, with growth in Annualised Premium Equivalent (APE) but a decline in absolute value of new business (VNB) for the latest quarter. Around the same time, Motilal Oswal Financial Services (MOFSL) reiterated its ‘Buy’ stance but reduced its target price, citing regulatory uncertainty around commission caps. The combination of operating performance and the policy overhang has kept the stock in focus.

Media reports also noted SBI Life shares extended gains for a third consecutive session on March 18, supported by MOFSL’s reiterated call and a target that implied about 24% upside from the previous close. At the same time, the commentary flagged that near-term disruptions could emerge if bancassurance commission rules change.

Quarterly performance: APE grows, VNB slips

For the quarter, SBI Life reported 6% year-on-year growth in new business APE to INR57.5 billion. In the same period, absolute VNB declined 2% year-on-year to INR16.3 billion.

The VNB margin for the quarter came in at 28.3%, compared with 30.5% in 4QFY25. The note described the outcome as “in line”, and cited an estimate of 28.4% for the quarter’s VNB margin.

The quarter therefore showed a familiar trade-off for life insurers: premium-equivalent growth continued, but value creation per unit of new business moderated versus the year-ago period.

FY26 full-year snapshot: growth stays healthy

For FY26, APE grew 13% year-on-year to INR242.7 billion. For the same year, VNB grew 12% year-on-year to INR66.7 billion.

The VNB margin for FY26 stood at 27.5%. This was described as the upper end of the company’s guidance band of 26% to 28%.

Guidance, margins, and what the brokerage is modelling

The provided material said MOFSL slightly cut its APE estimates and now expects roughly 14% CAGR over FY26-28E. This adjustment translated into a 2% decline in VNB and EV estimates for both FY27 and FY28.

Operating RoEV was expected to remain stable at 18% in that note. Separately, a “Brokerage Call Of The Day” segment also linked SBI Life’s growth and margin discipline to an 18% operating ROE view.

Target price revision: what changed

MOFSL reduced its target price on SBI Life to INR2,400 from INR2,570 per share, while reiterating ‘Buy’. The same write-up said this implied about 24% upside from the previous close.

Another line in the provided text also mentioned a revised target price of INR2,350, based on 2.1x FY28E P/EV, while still reiterating a ‘Buy’ view. The common thread across both references was that the rating remained positive, but the target was trimmed.

Commission caps and bancassurance: the key near-term risk

MOFSL flagged that the implementation of commission caps could disrupt bancassurance economics. Since bancassurance is a meaningful distribution lever for large insurers, changes to commissions can affect product pricing, distributor incentives, and the pace of branch-led new business.

The risk is not theoretical in market behaviour. The text noted that in November 2024, SBI Life shares fell over 6% on reports around possible restrictions on bank insurance business.

Industry and company context: growth versus valuation

The material stated SBI Life delivered 15% APE growth over FY20 to FY25, compared with an industry average of 6%. It also said that in FY26 so far, SBI Life’s APE growth was 15% versus the industry’s 13%, and MOFSL expected APE growth to remain around 15% annually through FY28.

On market size, the text projected India’s life insurance market could reach $144.5 billion by 2031. It also said SBI Life’s market value was INR1,940 billion as of March 17, 2026.

Valuation metrics were also highlighted. SBI Life’s P/E was stated to be about 78.16 as of March 17, 2026. The same section warned that a high valuation can amplify downside if growth slows or regulatory issues become more severe.

Cost and profitability signals investors tracked

The material pointed to operating cost pressure in Q3 FY26, stating operating expenses rose 45.6%, which directly weighed on profit margins.

It also compared profitability ratios: HDFC Life was stated to have 17.3% ROE and 18.3% ROCE, while SBI Life had 14.35% ROE and 17% ROCE.

What other analysts were saying

The text said market opinions were mixed. Prabhudas Lilladher reportedly had a ‘Hold’ rating with a target of INR2,125, while MarketsMOJO also indicated a ‘Hold’ view due to valuation and industry pressures.

It also mentioned a broader set of targets, stating price objectives from brokerages such as Nuvama and JM Financial were in the INR2,200 to INR2,320 range.

Key numbers at a glance

Market impact: what matters for investors

The immediate market read-through is that SBI Life’s premium-equivalent growth remained intact, but value metrics softened in the quarter as margins moved down versus 4QFY25. For investors, that puts attention on whether the product mix shift and protection growth can support margins, especially if distribution economics change.

The regulatory angle is central because bancassurance is a core channel across the sector, and commission caps can alter how aggressively insurers and banks push certain products. Alongside this, the stock’s valuation, as cited in the material, raises the sensitivity to any disappointment on growth, margins, or cost control.

Why the story matters

SBI Life sits at the intersection of two powerful forces: a structurally growing life insurance market and a distribution-led business model that can be affected by regulation. The FY26 numbers cited show the company is still growing APE and VNB on a full-year basis, with FY26 VNB margin at the upper end of guidance.

But the quarter-level margin drop and the cited jump in operating costs in Q3 FY26 underline how quickly profitability optics can change. That is why target-price cuts can happen even when ratings remain supportive.

Conclusion

SBI Life’s reported quarter showed APE growth of 6% year-on-year with a lower VNB margin than the year-ago quarter, while FY26 delivered double-digit APE and VNB growth with margins within guidance. MOFSL reiterated ‘Buy’ but reduced its target price, pointing to commission-cap risks and the need to balance growth with margins and cost discipline. The next set of updates on regulatory rules and distribution economics will remain key inputs for how the stock is priced.